• Lisinopril Dihydrate: From ACE Inhibition to Translation

  2026-09-29

  Lisinopril dihydrate offers a mechanistically interpretable way to interrogate the renin–angiotensin system across hypertension research, heart failure research, acute myocardial infarction research, and diabetic nephropathy models. This thought-leadership guide connects nanomolar ACE inhibition with assay design, comparator selection, and translational decision-making.

• LMO2–LDB1 Signaling in Acute Myeloid Leukemia

  2026-09-29

  The reference study defines an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia (AML), rather than treating LMO2 only as a prognostic marker. By combining genetic perturbation, protein-interaction analysis, rescue experiments, and transcriptomic and chromatin profiling, it connects this complex to AML cell survival, proliferation, colony formation, and apoptosis-related gene regulation.

• Angiotensin 1/2 (1-6): Assay Strategy

  2026-09-28

  Explore how Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, can be used to design more discriminating renin-angiotensin system and receptor-binding studies. This guide translates recent spike–AXL binding findings into practical assay controls while separating biochemical evidence from physiological interpretation.

• Diminazene Aceturate in ACE2 and Parasite Research

  2026-09-28

  Diminazene Aceturate offers a useful research bridge between trypanocidal assays and investigation of ACE2-associated cardiac protection—but those are distinct experimental questions. This guide turns the reported sepsis-cardiomyopathy findings into a practical workflow, with formulation checks, assay choices, and controls that help separate pathway evidence from compound effects.

• Diminazene Aceturate: Practical Research Workflows

  2026-09-27

  Diminazene Aceturate offers a useful experimental bridge between trypanosome parasite research and investigations of ACE2-linked cardiac biology—but those applications require separate controls and cautious interpretation. This workflow guide turns the February 2024 sepsis-cardiomyopathy findings into practical assay choices, handling steps, and troubleshooting checks without treating preclinical results as clinical evidence.

• Gastrodin, Microglia, and Astrocyte RAS–SIRT3

  2026-09-26

  A 2024 study used microglial conditioned medium and AT1-receptor inhibition to examine how gastrodin alters renin–angiotensin system (RAS) and inflammatory markers in reactive astrocytes. The results connect microglia-to-astrocyte signaling with RAS–SIRT3 regulation, while leaving important questions about pathway causality and in vivo relevance open.

• GPR107 Loss Promotes Diabetic Nephropathy

  2026-09-25

  Xu et al. report that GPR107 deficiency worsens diabetic kidney injury by impairing clathrin-mediated internalization of AT1R in podocytes, shifting collagen IV production and degradation toward extracellular accumulation. The findings connect receptor trafficking to glomerular basement membrane remodeling and suggest a mechanism to test in future diabetic nephropathy research.

• Losartan Beyond Blood Pressure: Testing Matrix Biology

  2026-09-25

  Losartan is more than an angiotensin II receptor antagonist for hypertension research: its use in a tumor hydrogel study raises new questions about how to measure extracellular-matrix remodeling. Explore the study’s practical assay implications, experimental limits, and ways to interpret Losartan’s effects across cardiovascular and tumor biology.

• Dexamethasone Workflows for Inflammation Research

  2026-09-24

  Build more interpretable inflammation assays with practical Dexamethasone treatment, vehicle-control, and readout strategies. The workflow connects glucocorticoid signaling studies with a recent natural-product macrophage study—while keeping their evidence and potency claims distinct.

• Angiotensin III: Practical RAAS Assay Workflows

  2026-09-24

  Use Angiotensin III to probe aldosterone release, receptor signaling, and a newly reported angiotensin-peptide effect on spike–receptor binding. This workflow-oriented guide separates established RAAS biology from exploratory assay recommendations and shows how to handle the peptide for reproducible results.

• Acetylcholine Chloride for Reproducible Assays

  2026-09-23

  Learn how to use Acetylcholine Chloride (SKU B1596) as a controlled cholinergic stimulus in cell-based and neuroscience workflows without confusing receptor activation with a viability readout. Practical guidance covers experimental controls, handling, interpretation of gut–brain findings, and product selection.

• JNJ-26481585 (Quisinostat) Research Workflows

  2026-09-23

  Learn how to deploy JNJ-26481585 (Quisinostat) as an epigenetic modulator for apoptosis, proliferation, and drug-resistance studies. This workflow connects HDAC inhibition with the TRIM21–ERK1/2 axis while emphasizing assay controls, formulation, and troubleshooting.

• SU6656: From Src Biology to Translational Strategy

  2026-09-22

  SU6656 is more than a catalog-listed Src tyrosine kinases inhibitor: it is a mechanistic probe connecting Src-regulated proliferation, megakaryocyte polyploidization, endothelial survival, and tumor vascular response. This thought-leadership article translates the available evidence into a disciplined framework for platelet-production research, cancer research, and radiotherapy development while distinguishing validated findings from forward-looking experimental opportunities.

• SCH772984 HCl: ERK1/2 Inhibitor Workflows

  2026-09-22

  SCH772984 HCl provides a nanomolar, mechanism-focused way to suppress ERK1/2 signaling in BRAF- and RAS-driven cancer models while enabling carefully timed studies of TERT regulation in human pluripotent stem cells. This guide connects pathway inhibition with phosphorylation, proliferation, chromatin, and transcriptional readouts, plus practical controls for reproducible experiments.

• Evacetrapib and the Ferroptosis Threshold

  2026-09-21

  A translational framework for interpreting hydrogen sulfide–driven ferroptosis in non-small cell lung cancer and positioning Evacetrapib (LY2484595) as an exploratory orthogonal reagent rather than an overclaimed pathway substitute.

7775 records 1/519 page Next 12345 下5页 Last page